Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr.

Novavax’s (NVAX) stock is up after the FDA requested additional data for its COVID-19 vaccine. Unusual at first glance, the phrase “additional data” tends to inspire fear among biotechnology investors ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...